Tulshidas S. Patil*

Dr. Tulshidas S. Patil*

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TPTulshidas S. Patil*
Tulshidas S. Patil*
ADAshwini Deshpande
Ashwini Deshpande


Verified
Journal Article
Open access
PDF file
TPTulshidas S. Patil*
Tulshidas S. Patil*
NGNayan A. Gujarathi
Nayan A. Gujarathi
Abhijeet A. AherAbhijeet A. Aher
Abhijeet A. Aher
HPHemal E. Pachpande
Hemal E. Pachpande
CSCharu Sharma
Charu Sharma
YGYogeeta Agrawal Goyal
Yogeeta Agrawal Goyal
Psoriasis is linked with unusual differentiation and hyperproliferation of epidermal keratinocytes that significantly impair the quality of life (QoL) of patients. The present treatment options only provide symptomatic relief and are surrounded by various adverse effects. Recently, nanostructured lipid carriers (NLCs) have emerged as next-generation nanocarriers with better physicochemical characteristics. The current manuscript provides background information on psoriasis, its pathophysiology, existing treatment options, and its limitations. It highlights the advantages, rationale, and mechanism of the permeation of NLCs for the treatment of psoriasis. It further gives a detailed account of various NLC nanoformulations for the treatment of psoriasis. In addition, tabular information is provided on the most relevant patents on NLCs for treating psoriasis. Lastly, light is shed on regulatory considerations related to NLC-like nanoformulations. In the treatment of psoriasis, NLCs display a sustained release drug profile, an ability to incorporate both hydrophobic and hydrophilic drugs, an enhancement in skin hydration, penetrability, retention, and bioavailability of the drug, along with reduced staining potential as compared to conventional ointments, and decreased side effects of drug molecules. This affirms the bright future of NLC nanoformulations in the treatment of psoriasis. However, academic industry collaboration and more sound regulatory controls are required to commercialize the NLC nanoformulations for psoriasis treatment.

3 April 2018 in Journal of Drug Targeting
Verified
Journal Article
Closed access
TPTulshidas S. Patil*
Tulshidas S. Patil*
ADAshwini Deshpande
Ashwini Deshpande
SDShirish Deshpande
Shirish Deshpande
PSPravin K. Shende
Pravin K. Shende
Tuberculosis (TB) is a disease caused by the pathogen Mycobacterium tuberculosis. Prolonged administration of high dose antibiotics using oral and injectable routes and their associated side effects show limitations to successful treatment outcome of TB. Nanocarrier-based dry powder inhalers (DPIs) may provide a breakthrough as an alternative therapeutic approach because of their stable, non-invasive nature and ability to target the drug at the site of infection. The current review focuses on the roadmap of the respiratory system, drug deposition and targeting at the site of infection via the pulmonary route. This review will provide readers with an overview of the existing literature of nanocarrier-based DPIs of anti-TB drugs. Among different nanocarriers, results of most of the proliposomes and polymeric particles-based DPIs with respect to their characterisation parameters like encapsulation efficiency, drug loading, storage stability and aerodynamic properties are not encouraging, whereas surface engineered, nanostructured lipid carriers (NLCs), i.e. ligand attached-NLCs-based dry powder inhalers (NLCs-DPI) show promising results. But still, there is a need to investigate them for in vitro, ex vivo, in vivo and toxicity studies to achieve a market approval.

1 March 2021 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
TPTulshidas S. Patil*
Tulshidas S. Patil*
ADAshwini Deshpande
Ashwini Deshpande
Tuberculosis (TB) disease is caused due to the infection of Mycobacterium tuberculosis bacilli which reside in alveolar macrophages (AMs). Clofazimine (CLF) has been reinstated clinically for the treatment of TB. However, major challenge of using CLF is its severe side-effects after oral administration. The present research was aimed to establish the safety and enhance the bioavailability of CLF by loading it into nanostructured lipid carriers (CLF-NLCs) and mannosylated NLCs (M-CLF-NLCs) to selectively target the drug toward AMs. The safety of CLF-NLCs and M-CLF-NLCs was evaluated by in vitro hemocompatibility studies, cell viability studies on macrophage J774 cell lines, and in vivo acute inhalation toxicity studies. The bioavailability was estimated by single-dose pharmacokinetics and biodistribution studies. Hemocompatibility studies showed normal RBCs count and least hemolysis of 0.23 ± 0.081% for M-CLF-NLCs treated group. Cell viability studies revealed greater safety of NLCs than CLF-drug dispersion in the concentration range of 2.5–25 μg/ml. In vivo acute toxicity studies revealed no physiological or behavioral changes and no mortality recorded over 14 days period. In pharmacokinetic studies, a maximum concentration of the drug (Cmax) of 35.44 ± 0.34 μg/g from M-CLF-NLCs after 48 h and longer residence time in lung tissues observed due to its sustained release and mannose receptor-mediated endocytosis. M-CLF-NLCs showed a maximum AUC0–∞ value of 2691.83 h μg/ml in lungs that indicated twofold greater bioavailability as compared to CLF-drug dispersion. Thus, mannosylated NLCs can be used as promising carriers for the safe and effective delivery of CLF via inhalation route for the management of TB disease.

5 June 2020 in Materials Technology
Verified
Journal Article
Closed access
TPTulshidas S. Patil*
Tulshidas S. Patil*
ADAshwini Deshpande
Ashwini Deshpande
The Mycobacterium Tuberculosis infection can be treated via clofazimine (CLF)-loaded nanostructured lipid carriers (NLCs). Precipitation-hot microemulsification-probe sonication method was employed for formulation of CLF-NLCs and optimised by using 33 Box–Behnken design. The surface of CLF-NLCs was modified with mannose ligands. The mannose modified and bare CLF-NLC formulations show highest encapsulation efficiencies greater than 70%. The preliminary evaluations were performed by using analytical techniques like Fourier transform infrared spectroscopy, differential scanning colorimetry, and powder X-ray diffraction studies. In-vitro drug release studies showed pH-dependent, sustained drug release profiles and best fitted for first order and Higuchi kinetics. The spherical morphologies of NLCs were confirmed by field-emission scanning electron microscopy. The formulations showed high storage stability at ambient and refrigerated conditions. Thus, present research successfully demonstrated the application of QbD principles in developing CLF-NLCs and improved the performance of CLF.